Logo Image
Opinion|Videos|January 24, 2025

Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.

Episodes in this series

Video content above is prompted by the following:

  • Aflibercept 8 mg was evaluated in the PULSAR and PHOTON trials for neovascular age-related macular degeneration and diabetic macular edema. Could you briefly review the design of these trials?

Related Content

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
Video

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

View more
Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
Video

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS

View more
(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
Video

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

View more
(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
Video

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

View more
(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
Video

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

View more
Retina Updates in Montréal
In-Person + Virtual Event

Retina Updates in Montréal

July 16-17, 2026

View more
PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence
Video

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

View more
Interventional Dry Eye: A Stepwise Treatment & Management Approach
Video

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO

View more
Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
Video

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

View more
(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
Video

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

View more
(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
Video

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

View more
(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
Video

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

View more
(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
Video

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

View more
(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
Video

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

View more
Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO
Video

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

View more
(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis
Video

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

View more
(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis
Video

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

View more
Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy
Video

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

View more
Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
Video

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

View more